Provectus Biopharmaceuticals’ PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at European Society for Medi...
July 23 2014 - 9:13AM
Business Wire
Poster Presentation Scheduled for Sunday,
September 28, 2014, From 12:45 To 1:45 pm
ESMO 2014 Congress in Madrid, Spain, Runs
from September 26-30, 2014
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT)
(www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company (the "Company" or "Provectus"), will have
clinical data on PV-10 presented at the European Society for
Medical Oncology’s 2014 Congress in Madrid, Spain.
The presentation, titled "Subgroup efficacy in patients
receiving intralesional rose bengal to all existing melanoma in
phase II study PV-10-MM-02," will be held on Sunday, September 28,
2014, beginning at 12:45 pm local time.
Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is happy
to see our PV-10 data on melanoma shared with those attending the
ESMO Congress this year."
PV-10, a 10% solution of Rose Bengal that is currently being
examined as a novel cancer therapeutic, is designed for injection
into solid tumors (intralesional administration), thereby reducing
potential for systemic side effects.
About the European Society for Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading
European professional organization committed to advancing the
specialty of medical oncology and promoting a multidisciplinary
approach to cancer treatment and care.
ESMO’s mission is to advance cancer care and cure through
fostering and disseminating good science that leads to better
medicine and determines best practice.
ESMO’s scientific journal, Annals of Oncology, ranks among the
top clinical oncology journals worldwide. ESMO events are the
meeting place in Europe for medical oncologists to update their
knowledge, to network and to exchange ideas.
To find out more about ESMO, please visit: www.esmo.org
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug
for cancer, is designed for injection into solid tumors
(intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast
cancer and cancers of the liver. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and
atopic dermatitis. Provectus has recently completed Phase 2 trials
of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a
topical treatment for atopic dermatitis and psoriasis. Information
about these and the Company's other clinical trials can be found at
the NIH registry, www.clinicaltrials.gov. For additional
information about Provectus please visit the Company's website at
www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
“forward-looking statements” as defined under U.S. federal
securities laws. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and
express management’s current views of future performance, results,
and trends and may be identified by their use of terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “will,” and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2013, and in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2014), and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with a
phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma
and the costs associated with such a trial if it is necessary;
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as liver cancer, if such licensure is appropriate considering
the timing and structure of such a license, or to commercialize
PV-10 on our own to treat melanoma and other solid tumors such as
liver cancer;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999, ext. 30orPorter, LeVay & Rose, Inc.Marlon
Nurse, DM, SVP – Investor Relations212-564-4700orBill Gordon –
Media Relations212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024